FFO
SGMO

Fortitude Family Office’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Fortitude Family Office’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,126
Closed -$473 – 2054
2025
Q4 		$473 Buy
+1,126
New +$597 ﹤0.01% 1735

Other funds holding SGMO

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Fortitude Family Office's SGMO Position: Q1 2026 in Review

Fortitude Family Office sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q1 2026, closing a stake of 1,126 shares — an estimated $473 sold.

Fortitude Family Office first reported a position in SGMO in Q4 2025 and held it in 1 quarter. The position peaked at $473 in Q4 2025. 112 funds tracked by Wall St. Rank hold SGMO as of Q1 2026.

  • Fortitude Family Office reported no remaining SANGAMO THERAPEUTICS INC position as of Q1 2026 after selling out during the quarter.
  • Fortitude Family Office sold 1,126 SANGAMO THERAPEUTICS INC shares in Q1 2026, an estimated $473.
  • Fortitude Family Office first reported a position in SANGAMO THERAPEUTICS INC in Q4 2025 and held it in 1 quarter.
  • Fortitude Family Office's SANGAMO THERAPEUTICS INC position peaked at $473 in Q4 2025.
  • 112 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2026.

Based on Fortitude Family Office's 13F filing for Q1 2026, filed 16 Apr 2026.